Study Objective: Despite numerous advances in out-of-hospital combat care, exsanguinating hemorrhage continues to be the leading cause of preventable death on the battlefield. This gap in emergent care was highlighted by the Defense Health Board. In its Combat Trauma Lessons Learned from Military Operations 2001-2013, the board emphasized that continued research within the areas of non-compressible hemorrhage, novel hemostatic dressings, and junctional hemorrhage control was mission critical. This pilot study examined the use of a novel hemostatic device that could be used to help fill this gap in critical care. The iTClamp™ provides direct mechanical closure of soft tissue wounds. It has recently received FDA approval as a hemorrhage control device; however, there is limited data validating its efficacy and defining its role among the numerous other hemorrhage control products. This pilot was developed to assess feasibility, logistical considerations, and device limitations when applying the iTClamp to neck, groin, and axilla wounds in a well-established porcine model of severe hemorrhage. This is of particular importance as the device’s mechanism differs from other hemorrhage control devices.Methods: The hemostatic strategies tested include the iTClamp used in conjunction with either QuickClot Combat Gauze® or XStat® sponges. We applied the iTClamp to 12 wounds, either 5cm or 10 cm in length, combined with either Combat Gauze or XStat sponge packing.Results: Hemostasis was achieved in 11 of the 12 applications, although we needed to adjust the device placement in some of the sites.Conclusion: Preliminary results suggest that the iTClamp can be utilized in conjunction with other hemostatic agents. This pilot study identified potential limitations as well as numerous areas for future study. Study Objective: Despite numerous advances in out-of-hospital combat care, exsanguinating hemorrhage continues to be the leading cause of preventable death on the battlefield. This gap in emergent care was highlighted by the Defense Health Board. In its Combat Trauma Lessons Learned from Military Operations 2001-2013, the board emphasized that continued research within the areas of non-compressible hemorrhage, novel hemostatic dressings, and junctional hemorrhage control was mission critical. This pilot study examined the use of a novel hemostatic device that could be used to help fill this gap in critical care. The iTClamp™ provides direct mechanical closure of soft tissue wounds. It has recently received FDA approval as a hemorrhage control device; however, there is limited data validating its efficacy and defining its role among the numerous other hemorrhage control products. This pilot was developed to assess feasibility, logistical considerations, and device limitations when applying the iTClamp to neck, groin, and axilla wounds in a well-established porcine model of severe hemorrhage. This is of particular importance as the device’s mechanism differs from other hemorrhage control devices. Methods: The hemostatic strategies tested include the iTClamp used in conjunction with either QuickClot Combat Gauze® or XStat® sponges. We applied the iTClamp to 12 wounds, either 5cm or 10 cm in length, combined with either Combat Gauze or XStat sponge packing. Results: Hemostasis was achieved in 11 of the 12 applications, although we needed to adjust the device placement in some of the sites. Conclusion: Preliminary results suggest that the iTClamp can be utilized in conjunction with other hemostatic agents. This pilot study identified potential limitations as well as numerous areas for future study.